难处理高血栓负荷患者早期预测及预后的研究

注册号:

Registration number:

ChiCTR2200060750 

最近更新日期:

Date of Last Refreshed on:

2023-03-20 21:30:59 

注册时间:

Date of Registration:

2022-06-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

难处理高血栓负荷患者早期预测及预后的研究

Public title:

Clinical study for early prediction and prognosis of refractory high thrombus burden

注册题目简写:

English Acronym:

研究课题的正式科学名称:

难处理高血栓负荷患者早期预测及预后的研究

Scientific title:

Clinical study for early prediction and prognosis of refractory high thrombus burden

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

司道远 

研究负责人:

贺玉泉 

Applicant:

Daoyuan Si 

Study leader:

Yuquan He 

申请注册联系人电话:

Applicant telephone:

+86 13578949866

研究负责人电话:

Study leader's
telephone:

+86 13944145413

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sidaoyuan1984@sina.com

研究负责人电子邮件:

Study leader's E-mail:

heyq@jlu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

吉林省长春市二道区仙台大街126号

研究负责人通讯地址:

吉林省长春市二道区仙台大街126号

Applicant address:

126 Xiantai Street, Erdao District, Changchun, Jilin

Study leader's address:

126 Xiantai Street, Erdao District, Changchun, Jilin

申请注册联系人邮政编码:

Applicant postcode:

130031

研究负责人邮政编码:

Study leader's postcode:

130031

申请人所在单位:

吉林大学中日联谊医院

Applicant's institution:

China-Japan Union Hospital of Jilin University

研究负责人所在单位:

吉林大学中日联谊医院

Affiliation of the Leader:

China-Japan Union Hospital of Jilin University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20220118018

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

吉林大学中日联谊医院伦理委员会

Name of the ethic committee:

Ethics Committee of China-Japan Union Hospital of Jilin University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-01-18 00:00:00

伦理委员会联系人:

许焯

Contact Name of the ethic committee:

Zhuo Xu

伦理委员会联系地址:

吉林省长春市二道区仙台大街126号

Contact Address of the ethic committee:

126 Xiantai Street, Erdao District, Changchun, Jilin

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

吉林大学中日联谊医院

Primary sponsor:

China-Japan Union Hospital of Jilin University

研究实施负责(组长)单位地址:

吉林省长春市二道区仙台大街126号

Primary sponsor's address:

126 Xiantai Street, Erdao District, Changchun, Jilin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

吉林

市(区县):

长春

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

吉林大学中日联谊医院

具体地址:

吉林省长春市二道区仙台大街126号

Institution
hospital:

China-Japan Union Hospital of Jilin University

Address:

126 Xiantai Street, Erdao District, Changchun, Jilin

经费或物资来源:

吉林省发改委

Source(s) of funding:

Development and Reform Commission of Jilin Province

研究疾病:

冠状动脉性心脏病  

Target disease:

Coronary heart disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

寻找急性ST段抬高型心肌梗死患者难处理血栓的预测因子并评估预后。  

Objectives of Study:

To investigate the predictors of refractory thrombus in STEMI patients and to evaluate the prognosis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

6个月内有重大手术或外伤史、肿瘤病史、活动性感染、肝肾功能衰竭等。

Exclusion criteria:

History of surgery or trauma within 6 months, history of malignant tumor, active infection, renal failure and liver failure.

研究实施时间:

Study execute time:

From 2022-06-01 00:00:00 To 2022-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-01 00:00:00 To 2022-12-01 00:00:00

干预措施:

Interventions:

组别:

难处理血栓组

样本量:

15

Group:

Refractory thrombus group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

对照组

样本量:

45

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

吉林省 

市(区县):

长春市 

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

吉林大学中日联谊医院 

单位级别:

三级甲等 

Institution
hospital:

China-Japan Union Hospital of Jilin University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

左心室射血分数

指标类型:

主要指标

Outcome:

left ventricular ejection fraction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主要不良心血管事件

指标类型:

主要指标

Outcome:

Major adverse cardiovascular events

Type:

Primary indicator

测量时间点:

随访期间

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

-

Randomization Procedure (please state who generates the random number sequence and by what method):

-

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后1年内,酌情采用网络平台,临床试验公共管理平台 Resman, http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 1 year after the trial completing, Web-based pubulic database as appropriate, Resman, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

吉林省心血管疾病研究所的数据安全管理委员会

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data safety and monitoring in Jilin Provincial Cardiovascular Disease Research Center

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-06-09 18:31:30